ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluorouracil

Also written as “5-Fluorouracil”, “fluorouracil” and “5-fluorouracil”.

Its studies are mostly in Colorectal Neoplasms · Pancreatic Neoplasms · Neoplasms · Head and Neck Neoplasms · Stomach Neoplasms, led by 12 companies.

Drug pageFluorouracil: every studyMany companies study it; this page follows only the 34 they lead. All 763 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 14, 200634 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only160 open or runningphase 4since Sep 14, 2006Jan 6, 2001none ahead
Pfizerits history only51 open or runningphase 3since Jan 28, 2000Jan 28, 2000none ahead
Jiangsu HengRui Medicineits history only21 open or runningphase 3since Feb 20, 2023Mar 8, 2021none ahead
Otsukaits history only20 open or runningphase 3since Jun 2, 2000Jun 2, 2000none ahead
Prologue Research Internationalits history only20 open or runningphase 3since Jun 5, 2003May 6, 2001none ahead
Almirall10 open or runningphase 3since Nov 10, 2014Nov 10, 2014none ahead
CbsBioscienceits history only10 open or runningphase 2since Nov 10, 2016Nov 10, 2016none ahead
Encube Ethicals Pvt.its history only10 open or runningphase 3since Sep 23, 2021Sep 23, 2021none ahead
HealthCare Global Enterpriseits history only10 open or runningphase 2since Sep 29, 2016Sep 29, 2016none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 3since Feb 25, 2019Feb 25, 2019none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, Baili-Bio (Chengdu) Pharmaceutical, Quintiles, Takeda, Almirall Hermal and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Almirall only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2014First study: phase 3 study in Keratosis, ActinicFirst studyNCT02289768 · 166 enrolled · Germany, United Kingdom

TargetBeta

TYMS →read by rule
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
CapecitabineruleHoffmann-La Rochephase 4129
TegafurruleOtsukaphase 325

Studies

The one study Almirall leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02289768Keratosis, Actinic · Germany, United Kingdom3CompletedSep 2015166

How it is read

Names in the registry

  • “5-Fluorouracil”, 10 entries
  • “fluorouracil”, 9 entries
  • “Fluorouracil”, 8 entries
  • “5-fluorouracil”, 7 entries
  • “5-FU”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.